Epigral Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - As of December 31, 2025, Epigral's net debt was INR 557 crores with a net debt to EBITDA ratio of 1x, indicating a comfortable debt position. - The company is focused on capex projects including capacity expansion in CPVC and epichlorohydrin and wind solar hybrid power plants, progressing on schedule within budget. - No explicit indication in the call regarding raising funds via equity or additional debt. - Management emphasizes disciplined capital efficiency and execution to fund growth internally. - Any new capex plans will be finalized and announced in the coming months, but there's no mention of external fundraising for these.

- Capex of INR 337 crores spent; ongoing capex plans progressing as per schedule. - Projects to double capacity at CPVC and epichlorohydrin, and wind solar hybrid power plants on track for commissioning within announced timeline and budget. - Chlorotoluene value chain plant commissioned in March 2025, expected to contribute significantly to profit from FY27 onwards. - New projects’ capex plans are being finalized, with details expected to be announced in the coming months. - These investments aim to enhance integrated complex, extend value chain, and drive strong growth from FY27 onward, with significant growth expected from FY29 onward. - Strategy targets 70% revenue contribution from derivatives and specialty business through expansion and diversification.

- FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued demand. - Q4 FY '26 volumes likely to improve with uptick in demand from mid-November and better market conditions. - CPVC demand projected to grow 10-12% annually, anticipated to reach around 320,000 tonnes by FY '27 end, with long-term growth towards 500,000 tonnes by FY '30. - Chlorotoluene segment expected to contribute sizable revenue from FY '27 onwards, with major orders and contracts starting Q1 FY '27. - Epigral is commissioning expansions in CPVC and epichlorohydrin capacity; initial lower utilization expected post-commissioning but achieving optimal utilization within 1-2 years. - New projects and value chain extensions set to drive significant growth from FY '29 onwards. - Overall, management anticipates consistent growth aligned with expansion, diversification, and improving market demand.

- Epigral is targeting consistent growth through expansion and diversification across multiple products and industries (Page 17). - Q4 FY26 expected to see better volume and margin recovery after Q3 challenges (Pages 12-13). - Margins expected to improve to around 21%-23% in Q4 and onwards (Page 13). - Chlorotoluene value chain plant commissioned March 2025, expected to contribute sizably to profits starting FY27 (Page 4). - New capacities for CPVC and epichlorohydrin doubling planned, expected to be optimally utilized within 1-2 years, supporting revenue growth (Pages 7-9). - Volume growth anticipated in FY27 due to recovery in demand after subdued FY26 (Page 13). - New projects and expanded integrated complex set to drive significant growth from FY29 onwards (Page 4). - Management expects improvement in overall performance and profitability from FY27 onwards onward (Pages 4, 13, 17).

- Chlorotoluene segment orders are currently on a quarterly basis as customers are testing and building confidence. - Actual deliveries are happening on a full truckload basis, not just samples. - Major volume orders and long-term contracts are expected to begin from FY '27 onwards. - The company anticipates a sizable revenue contribution from the chlorotoluene plant starting Q1 FY '27. - As approvals and customer contracts finalize, order visibility will improve by March. - The management is cautious about making firm commitments on orderbook percentages before contracts finalize. - The increasing volumes in chlorotoluene indicate growing acceptance, but long-term orderbook/build-up is still in progress.